HRT Financial’s Apimeds Pharmaceuticals US APUS Stock Holding History

HRT Financial’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$147K	Buy	+29,508	New	+$143K	﹤0.01%	3985
2025 Q4	–	Sell	-1,357	Closed	-$24K	–	4318
2025 Q3	$24K	Buy	+1,357	New	+$25.1K	﹤0.01%	2688

Other funds holding APUS

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.42B AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Ankerstar Wealth Leander, Texas $129M AUM 9.28% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

HRT Financial's APUS Position: Q3 2026 in Review

HRT Financial opened a new position in Apimeds Pharmaceuticals US (APUS) in Q3 2026: 29,508 shares worth $147K. The stake represents ﹤0.01% of the portfolio and ranks #3985 among its holdings. This is a return to the name: HRT Financial previously reported a position in APUS as recently as Q3 2025.

HRT Financial first reported a position in APUS in Q3 2025 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold APUS as of Q3 2026.

HRT Financial held 29,508 shares of Apimeds Pharmaceuticals US worth $147K as of Q3 2026.
Apimeds Pharmaceuticals US was a new HRT Financial position in Q3 2026.
Apimeds Pharmaceuticals US made up ﹤0.01% of HRT Financial's portfolio in Q3 2026, its #3985 holding.
HRT Financial first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and has held it in 2 quarters since.
8 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2026.

Based on HRT Financial's 13F filing for Q3 2026, filed 13 Nov 2026.